A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation

被引：0
|
作者：
Midori Nakagaki
Michael Barras
Cameron Curley
Jason P. Butler
Glen A. Kennedy
机构：
[1] Royal Brisbane and Women’s Hospital,Pharmacy Department, Level 1 Ned Hanlon Building
[2] The University of Queensland,Bone Marrow Transplant Unit, Level 5 Joyce Tweddell Building
[3] Royal Brisbane and Women’s Hospital,undefined
来源：
Supportive Care in Cancer | 2017年 / 25卷
关键词：
Stem cell transplantation; Antiemetics; Ondansetron; Palonosetron; Olanzapine; Nausea and vomiting;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：607 / 613
页数：6
相关论文
共 50 条
  • [41] RANDOMIZED DOUBLE-BLIND CROSSOVER ONDANSETRON-DEXAMETHASONE VERSUS ONDANSETRON-PLACEBO STUDY FOR THE TREATMENT OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN PEDIATRIC-PATIENTS WITH MALIGNANCIES
    ALVAREZ, O
    FREEMAN, A
    BEDROS, A
    CALL, SK
    VOLSCH, J
    KALBERMATTER, O
    HALVERSON, J
    CONVY, L
    COOK, L
    MICK, K
    ZIMMERMAN, G
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 1995, 17 (02) : 145 - 150
  • [42] Palonosetron and dexamethasone for the prevention of nausea and vomiting in patients receiving allogeneic hematopoietic stem cell transplantation
    Su-Peng Yeh
    Woei-Chung Lo
    Ching-Yun Hsieh
    Li-Yuan Bai
    Ching-Chan Lin
    Po-Han Lin
    Chen-Yuan Lin
    Yu-Min Liao
    Chang-Fang Chiu
    Supportive Care in Cancer, 2014, 22 : 1199 - 1206
  • [43] A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study
    Navari, Rudolph M.
    Einhorn, Lawrence H.
    Loehrer, Patrick J., Sr.
    Passik, Steven D.
    Vinson, Jake
    McClean, John
    Chowhan, Naveed
    Hanna, Nasser H.
    Johnson, Cynthia S.
    SUPPORTIVE CARE IN CANCER, 2007, 15 (11) : 1285 - 1291
  • [44] Palonosetron versus ondansetron for prophylaxis of postoperative nausea and vomiting in laparoscopic cholecystectomy: a non-inferiority randomized controlled trial
    Davolos, Francisco Jose Chiaradia
    Modolo, Norma S.
    Braz, Leandro G.
    do Nascimento Jr, Paulo
    BRAZILIAN JOURNAL OF ANESTHESIOLOGY, 2024, 74 (01):
  • [45] Aprepitant for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy
    Takako Inoue
    Madoka Kimura
    Junji Uchida
    Kazumi Nishino
    Toru Kumagai
    Junko Taniguchi
    Fumio Imamura
    International Journal of Clinical Oncology, 2017, 22 : 600 - 604
  • [46] Aprepitant for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy
    Inoue, Takako
    Kimura, Madoka
    Uchida, Junji
    Nishino, Kazumi
    Kumagai, Toru
    Taniguchi, Junko
    Imamura, Fumio
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2017, 22 (03) : 600 - 604
  • [47] A multicycle phase III study evaluating palonosetron vs ondansetron at preventing chemotherapy-induced nausea and vomiting in pediatric patients
    Kabickova, E.
    Wachtel, A.
    Basharova, E.
    Spinelli, T.
    Nicolas, P.
    Kovacs, G.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S237 - S237
  • [48] Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy
    Boccia, Ralph
    O'Boyle, Erin
    Cooper, William
    BMC CANCER, 2016, 16
  • [49] Olanzapine and palonosetron without dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: A proof-of-concept trial.
    Kim, Hee Jun
    Ha, Joo Young
    Oh, Edward Hyunseung
    Park, Song Ee
    Yi, Jun Ho
    Jang, Joung Soon
    Hwang, In Gyu
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [50] Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy
    Ralph Boccia
    Erin O’Boyle
    William Cooper
    BMC Cancer, 16
12345